Genetic anticancer vaccine
US5935569A · kind A · utility
2Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 1997 |
| Grant date | Aug 10, 1999 |
| Priority date | — |
| Expiry date | Nov 14, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Genetic anticancer vaccine for stimulation of patient's immune system to eradicate cancer, particularly malignant melanoma. The objective of the invention is genetic modification of allogeneic cancel cells by insertion of the two genes, one encoding human interleukin 6 and the other encoding soluble interleukin 6 receptor, which will be administered to patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.